NEW YORK (GenomeWeb News) – XDx today said that it has entered into a multi-year agreement with Laboratory Corporation of America to provide the firm's AlloMap test in North America.
Under the deal, the molecular expression test will be offered to heart transplant patients, who will be able to have their blood drawn at participating LabCorp sites across the US. In addition, LabCorp will be XDx's preferred third-party, non-hospital provider for phlebotomy and specimen processing for all XDx AlloMap molecular expression tests conducted in North America.
"Those heart transplant recipients eligible for our AlloMap test will enjoy access to and the greater convenience of more than 1,700 patient service centers," Pierre Cassigneul, president and CEO of XDx, said in a statement.
The agreement follows a one-year pilot program at select LabCorp blood draw sites.
Brisbane, Calif.-based XDx said that its reference lab will continue to perform the AlloMap test.
The firm received US Food and Drug Administration clearance in 2008 for the AlloMap test for heart transplant patients. It plans to pursue development of other gene expression-based tests for autoimmune diseases including lupus.